Document:

Exhibit

Exhibit 10.1

M E M O R A N D U M    
                 
	
		
	TO:
	________________________________

	 
	 

	FROM:
	Compensation Committee

	 
	 

	DATE:
	March ___, 2016

	 
	 

	RE:
	Management Incentive Plan

	 
	 

 
You have been selected to participate in the LKQ Corporation Management Incentive Plan (“MIP”) for purposes of your potential 2017 bonus. The potential bonus described in this letter is subject to all of the terms and conditions set forth in this memorandum and in the MIP (a copy of which is attached to this memorandum). In the event of any inconsistency between the terms and conditions of the MIP and this memorandum, the terms and conditions of the MIP shall control.                               
	
				
	Performance Period:
	 
	 
	January 1, 2017 to December 31, 2017

	 
	 
	 
	 

	Award Components:
	 
	 
	The diluted earnings per share from continuing operations of LKQ Corporation ("EPS") for the Performance Period; provided, however,that EPS shall be increased to the extent that EPS was reduced in accordance with GAAP by objectively determinable amounts (in manner consistent with Section 162(m) of the Internal Revenue Code), in each case due to:

	 
	 
	 
	 

	 
	1.
	 
	A change in accounting policy or GAAP;

	 
	2.
	 
	Dispositions of assets or businesses;

	 
	3.
	 
	Asset impairments;

	 
	4.
	 
	Amounts incurred in connection with any financing;

	 
	5.
	 
	Losses on interest rate swaps resulting from mark to 
market adjustments or discontinuing hedges;

	 
	6.
	 
	Board approved restructuring, acquisition or similar charges including but 
not limited to charges in conjunction with 
or in anticipation of an acquisition;

	 
	7.
	 
	Losses (and related fees and expenses) related to extraordinary 
environmental, legal, product liability 
or other contingencies;

	 
	8.
	 
	Changes in corporate tax laws and regulations;

	 
	9.
	 
	A Board approved divestiture of a material business (i.e. 
the performance goals will be adjusted to account for the 
divestiture, including, if appropriate, the pro-rata effect 
of targeted improvements);

	 
	10.
	 
	Changes in contingent consideration liabilities;

	 
	11.
	 
	Losses from discontinued operations;

	 
	12.
	 
	The imposition of tariffs or taxes on the importation of inventory;

	 
	13.
	 
	Amortization expense related to acquired intangibles; and

	 
	14.
	 
	Other extraordinary, unusual or infrequently occurring 
items as specifically disclosed in the Company's
financial statements or filings under the Securities 
Exchange Act of 1934.

                

	
				
	 
	 
	 
	In addition, the Compensation Committee shall adjust the
Performance Goals or other features of the award (a) that
relate to the value or number of the shares of common
stock of the Company to reflect any stock dividend, stock
split, recapitalization, combination or exchange of shares,
or other similar changes in such stock, and (b) to account
for changes in the value of foreign currencies of countries
in which we operate versus the U.S. dollar (using the
respective exchange rates as set forth in the Company’s
budget approved by the Board of Directors on February 9, 2017).

	 
	 
	 
	 

	 
	 
	 
	Notwithstanding the foregoing, the Compensation
Committee, in its sole discretion, may reduce the actual
award payable to you below that which otherwise would be
payable pursuant to the Payout Formula or may eliminate
the actual award.

                               
 	
					
	Target Award:
	 
	 
	% of Base Salary

	Payout Formula:
	EPS($)
	 
	Percentage of Base Salary

	 
	Less Than
	 
	0Exhibit

Exhibit 10.2

M E M O R A N D U M

	
		
	TO:
	LTIP Participant

	 
	 

	FROM:
	Compensation Committee

	 
	 

	DATE:
	March ___, 2016

	 
	 

	RE:
	Long Term Incentive Plan

	 
	 

            
You have been selected to participate in the LKQ Corporation Long Term Incentive Plan (“LTIP”) for the 2017 to 2019 Performance Period.  The potential payout under your award is subject to all of the terms and conditions set forth in this memorandum and in the LTIP (a copy of which is attached to this memorandum).  In the event of any inconsistency between the terms and conditions of the LTIP and this memorandum, the terms and conditions of the LTIP shall control.
	
				
	Performance Period:
	 
	 
	January 1, 2017 to December 31, 2019

	 
	 
	 
	 

	Award Components:
	 
	 
	See the attached Award Component Matrix

	 
	 
	 
	 

	 
	 
	 
	Each of diluted earnings per share, revenue and return on equity shall be 
increased to the extent that it was reduced in accordance with GAAP by
objectively determinable amounts (in a manner consistent with Section 
162(m) of the Internal Revenue Code), in each case due to:

	 
	 
	 
	 

	 
	1.
	 
	A change in accounting policy or GAAP;

	 
	2.
	 
	Dispositions of assets or businesses;

	 
	3.
	 
	Asset impairments;

	 
	4.
	 
	Amounts incurred in connection with any financing;

	 
	5.
	 
	Losses on interest rate swaps resulting from mark to 
market adjustments or discontinuing hedges;

	 
	6.
	 
	Board approved restructuring, acquisition or similar charges including but 
not limited to charges in conjunction with 
or in anticipation of an acquisition;

	 
	7.
	 
	Losses (and related fees and expenses) related to extraordinary environmental, 
legal, product liability 
or other contingencies;

	 
	8.
	 
	Changes in corporate tax laws and regulations;

	 
	9.
	 
	A Board approved divestiture of a material business (i.e. 
the performance goals will be adjusted to account for the 
divestiture, including, if appropriate, the pro-rata effect 
of targeted improvements);

	 
	10.
	 
	Changes in contingent consideration liabilities;

	 
	11.
	 
	Losses from discontinued operations; 

	 
	12.
	 
	The imposition of tariffs or taxes on the importation of inventory; 

	 
	13.
	 
	Amortization expense related to acquired intangibles; and

	 
	14.
	 
	Other extraordinary, unusual or infrequently occurring 
items as specifically disclosed in the Company's
financial statements or filings under the Securities 
Exchange Act of 1934.

	
				
	 
	 
	 
	In addition, the Compensation Committee shall adjust the Award 
Components or other features of the award (a) that relate to the value or 
number of the shares of common stock of the Company to reflect any stock dividend, stock split, recapitalization, combination or exchange of shares, or 
other similar changes in such stock, and (b) to account for changes in the 
value of foreign currencies of countries in which we operate versus the U.S. 
dollar (using the 2016 average respective exchange rates).

	 
	 
	 
	 

	 
	 
	 
	Notwithstanding the foregoing, the Compensation Committee, in its sole
discretion, may reduce the actual award payable to you below that which
otherwise would be payable pursuant to the Award Component or may 
eliminate the actual award.Exhibit

Jounce Therapeutics, Inc.
Amended and Restated Non-Employee Director Compensation Policy
The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Jounce Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company.  This Policy will become effective (the “Effective Date”) upon approval by the Company’s Board of Directors (the “Board”).  In furtherance of this purpose, all non-employee directors shall be paid compensation for services provided to the Company as set forth below: This policy shall supersede any prior arrangements between the Company and the directors.
Cash Retainers
Annual Retainer for Board Membership:  $35,000 for general availability and participation in meetings and conference calls of our Board.  No additional compensation for attending individual Board meetings.  
Additional Annual Retainer for Non-Executive Chairperson of the Board: $30,000 to acknowledge the additional responsibilities and time commitment of the Chairperson role.
Additional Annual Retainers for Committee Membership:
	
		
	Audit Committee Chairperson
	$15,000

	Audit Committee member:
	$7,500

	Compensation Committee Chairperson:
	$10,000

	Compensation Committee member:
	$5,000

	Nominating and Corporate Governance Committee Chairperson:
	$8,000

	Nominating and Corporate Governance Committee member:
	$4,000

	No additional compensation for attending individual committee meetings.

All cash retainers will be paid quarterly, in arrears, or upon the earlier of resignation or removal of the non-employee director.  Cash retainers owing to non-employee directors shall be annualized, meaning that with respect to non-employee directors who join the Board during the calendar year, and with respect to all non-employee directors for 2017, such amounts shall be pro-rated based on the number of calendar days served by such director following the Effective Date.
Equity Retainers
Initial Option Grant: One-time option grant to each new non-employee director upon his/her election to the Board after the Effective Date to purchase 27,100 shares of common stock, par value $0.001 per share (the Common Stock”). Such initial option grant shall be made upon the director first becoming a director. Such initial option grant shall vest in equal quarterly installments during the 12 quarters following the grant date, subject to the director’s continued service on the Board.
On the date of each Annual Meeting of Stockholders:  Annual option grant to each non-employee director serving on the Board immediately following the Company’s annual meeting of stockholders to purchase 

13,550 shares of Common Stock. Such annual option grant shall vest on the earlier of the one-year anniversary of the grant date and the Company’s next annual meeting of stockholders, subject to the director’s continued service on the Board.    
All of the foregoing option grants will become immediately exercisable upon the death, disability of a director or upon a Sale Event (as defined in the Company’s 2017 Stock Option and Incentive Plan).  In addition, if the option grants described above are in the form of options to purchase the Company’s common stock, par value $0.001 per share (the “Common Stock”), to the directors will have until the earlier of one year following cessation of service as a director or the original expiration date of the option to exercise the option (to the extent vested at the date of such cessation), provided that the director has not been removed for cause.

Any stock option granted to a non-employee director pursuant to this Policy will be granted at an exercise price equal to the fair market value of a share of Common Stock on the date of grant. 

Expenses
The Company shall reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending Board and committee meetings.

ADOPTED AND EFFECTIVE:  March 8, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]